Ramucirumab (IMC 1121B, Cyramza) and Bevacizumab (Avastin). Epidermal Growth Factor Receptor (EGFR) pathway inhibitors. Panitumumab (Vectibix) and Cetuximab (Erbitux). We had Regorafenib (Stivarga) approved. A new colon cancer treatment medication TAS-102 (Lonsurf) is now approved. “I think we are getting access to new effective treatments for colon cancer that we didn’t have in the past.”
Transcript of video
New targeted chemotherapy for colon cancer: TAS-102, Lonsurf, Regorafenib, Stivarga, Ramucirumab, Cyramza, Panitumumab (Vectibix) and Cetuximab (Erbitux). molecular profiling of colon cancer helps to select EGFR, BRAF, anti-angiogenesis, multi-kinase inhibitors. Leading German-American colorectal cancer oncologist discusses new targeted chemotherapy for colon cancer. Antibodies that target the angiogenic pathway. Colorectal cancer targeted chemotherapy options. Advanced stage 4 colon cancer treatment by targeted chemotherapy. Medical second opinion confirms that colorectal cancer diagnosis at genetic level. Medical second opinion also confirms colon cancer cure is possible in metastatic colon cancer. Best precision medicine treatment for advanced stage 4 colon cancer with metastatic lesions. Medical second opinion helps to select a personalized medicine targeted treatment for stage 4 colorectal cancer with liver or lung metastases. Get medical second opinion on advanced colorectal cancer. Be confident that your precision medicine treatment is the best. Best colorectal cancer treatment by new BRAF inhibitors, EGFR inhibitor monoclonal antibodies, anti-angiogenesis medications and multikinase inhibitors. Video interview with leading expert in metastatic colorectal cancer treatment from California. Colorectal cancer new targeted medications. EGFR, VEGF, BRAF targeted treatment of colon cancer. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). We know that more effective targeted medications were developed to treat colorectal cancer. Their use with chemotherapy backbones increases the efficacy of tumor shrinkage incredibly. Such targeted colorectal cancer medications are antibodies that target the angiogenic pathway. Ramucirumab (IMC 1121B, Cyramza) and Bevacizumab (Avastin). There are also medications that target Epidermal Growth Factor Receptor (EGFR) pathway. Panitumumab (Vectibix) and Cetuximab (Erbitux). Over the last couple of years we are reaching 60% to 70% response rate of colorectal cancer tumors. It means 50% volume reduction of metastatic colon cancer tumors with our chemotherapy. Targeted chemotherapy opens even further the window for surgical treatment. The choice of chemotherapy in combination with new targeted medications is important for patients with newly diagnosed colon cancer. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). The choice of treatment makes a difference between life and death. That is a very important concept to understand. We are only beginning to use molecular profiling of colorectal cancer tumors. We already have introduced molecular tumor markers. They allow us to distinguish what antibodies would work most effectively in this colon cancer patient. Testing for KRAS and NRAS is now giving us the option to use EGF receptor inhibitors. They are Panitumumab (Vectibix) or Cetuximab (Erbitux). We are already making very nice progress to select and personalize chemotherapy for colon cancer. We decide on chemotherapy protocol after studying the molecular profile of the colorectal cancer tumor. But this is only the beginning. We already know we can identify additional molecular alterations in colon cancer tumors. Such molecular changes are not only are important for diagnosis of colon cancer. Molecular markers also predict the efficacy of new treatments. We had a publication in the New England Journal of Medicine. We showed that colorectal cancer tumor has a Microsatellite Instability (MSI). These patients have an unbelievable response to new immunomodulatory treatments. Microsatellite Instability means a mutation in DNA mismatch repair genes. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). I think the future of colon cancer treatment is extremely exciting. We understand and dissect out the colon cancer from one type of disease into many different colon cancer types. We know which patients will benefit differentially from new treatments for colon cancer. We will know which colon cancer treatment often has less toxicity and higher efficacy. This is an incredibly exciting time to be involved in colon cancer research. Because the old paradigm was simple. Patient with metastatic colorectal cancer will die. That paradigm is not true anymore. The progress in colon cancer treatment is huge. It is reflected in the new colorectal cancer clinical trials. Patient with newly diagnosed colon cancer now has the median survival over 30 months. Sometimes we look backwards for patients with colorectal cancer and no treatment. Their survival was 8 months. Over the last 10 years we quadrupled the median survival of patients with metastatic colon cancer. This is not even counting the patients who we cured completely from colorectal cancer. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). I think it’s a very new area of colon cancer research that opens up incredible opportunity in the future. We will not only develop new medications, but we will cure more patients with metastatic colon cancer. This year we already have seen incredible new data on new colon cancer treatment medications. In 2013 we had a new medication Regorafenib (Stivarga) approved. Regorafenib improved progression-free survival and overall survival of patients with colorectal cancer. We have another new colon cancer treatment medication approved. It is called TAS-102, trade name Lonsurf. The results of clinical trial for colon cancer treatment were published in the New England Journal of Medicine. Dr. Anton Titov, MD. New England Journal of Medicine (NEJM) is the most well known medical journal in the world. Dr. Heinz-Josef Lenz, MD (Colorectal Cancer Expert, California). That’s correct. NEJM publication is a really major accomplishment. Clinical trial results published in NEJM are usually the standard of care or the paradigm for disease treatment. This medication is called TAS-102 (Lonsurf). It also improved progression-free survival and overall survival of patients with colon cancer. I think we are getting access to new effective treatments for colon cancer. We didn’t have such cancer medicines in the past. These new colon cancer medications enrich our armamentarium of treatment options for patients with colorectal cancer. New targeted chemotherapy for advanced metastatic stage 4 colon cancer. Regorafenib (Stivarga), Ramucirumab (Cyramza), BRAF, multi-kinase inhibitors.